Abstract To observe the efficacy of Anti-VEGF therapy for different patterns of optical coherence tomography of diabetic macular edema, and to explore the relationship between the integrity of the ellipsoid zone (EZ) and visual acuity outcomes. A total of 90 affected eyes with DME who received anti-VEGF therapy were enrolled in this study. The examination of BCVA was according to Early Treatment Diabetic Retinopathy Study, and the results were recorded as logarithm of the minimum angle of resolution (logMAR). Spectral-domain OCT was used to measure central macular thickness (CMT) and assess the integrity of the ellipsoid zone.All eyes were classified into three groups based on OCT patterns: diffuse retinal thickening (DRT group, 29 eyes), cystoid macular edema (CME group, 30 eyes), and serous retinal detachment (SRD group, 31 eyes). All patients received an intravitreal injection of 0.05 ml (2.5 mg) conbercept.Changes in BCVA and CMT among the three groups were compared and analyzed at baseline and at 3, 6, and 12 months after treatment. The length of the EZ defect was measured. Based on the extent of EZ disruption, eyes were classified into three grades (0, 1, and 2) to analyze the correlation between EZ integrity and visual acuity. In addition, factors influencing post-treatment visual acuity were analyzed. Compared with the central macular thickness (CMT) before treatment, the CMT of the affected eyes was significantly decreased in the diabetic retinal thickening (DRT) group (t = 6.506, 4.134, 7.782, P 0.05). Anti-VEGF therapy could significantly improve the visual acuity of different patterns of DME, reduced the CMT, and had the best efficacy in the DRT group. There was relationship between the integrity of ellipsoid zone and the visual acuity outcomes.
Shi et al. (Fri,) studied this question.